NEW YORK, NY / ACCESSWIRE / July 19, 2024 / Lifshitz Law Firm
Teladoc Health, Inc. (NYSE:TDOC)
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made false and/or misleading statements and/or failed to disclose material information that: (i) the Company continued to expand its marketing spend throughout 2023, despite public assurances of that it would pull back its advertising spending; (ii) increased marketing spend on BetterHelp, an online mental health counseling service offered by Teladoc, deteriorated the Company's revenue, with little return for that investment; (iii) despite the Company's acknowledgment that increased advertising spend would be marginally inefficient due to market saturation, it continued to grow its advertising spend in the BetterHelp business; and (iv) despite public statements that there remained "a long runway" for BetterHelp membership growth, BetterHelp's membership stagnated and then decreased in 2023, due to market saturation, largely due to BetterHelp's own marketing.
If you are a TDOC investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.
Mobileye Global Inc. (NASDAQ:MBLY)
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) to avoid the shortages experienced amid supply chain constraints in 2021 and 2022, the Company's Tier 1 customers had purchased inventory in excess of demand during fiscal 2023; (ii) as a result, the Company's customers had excess inventory on hand, including approximately 6-7 million units of EyeQ SoCs; (iii) due to the build-up of inventory, there was a significant risk that the Tier 1 customers would buy less product, thus adversely impacting the Company's fiscal 2024 financial results; and (iv) as a result of the foregoing, the Company's positive statements about its business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you are a MBLY investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.
bluebird bio, inc. (NASDAQ:BLUE)
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made false and/or misleading statements that: (i) they could obtain FDA approval for lovocel without any box warnings for haematological malignancies; (ii) they would be granted a priority review voucher by the FDA and in turn sell it in order to strengthen their financial position for the lovocel launch; (iii) as a result, the Company significantly overstated Lyfgenia's clinical and/or commercial prospects; and (iv) therefore, the Company's public statements were materially false and misleading at all relevant times, and that as a result, shareholders purchased the Company's securities at artificially inflated prices.
If you are a BLUE investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.
Globe Life, Inc. (NYSE:GL)
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements concerning: (i) Globe Life's consistent premium revenue growth, particularly from AIL - the largest of Globe Life's subsidiaries; and (ii) Globe Life's Code of Business Conduct and Ethics. More specifically, the Compay repeatedly attributed its consistent premium revenue growth "to increased agent count and productivity." As a result of these misrepresentations, Globe Life common stock traded at artificially inflated prices during the Relevant Period.
If you are a GL investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.
ATTORNEY ADVERTISING.© 2024 Lifshitz Law PLLC. The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516) 493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact:
Joshua M. Lifshitz, Esq.
Lifshitz Law PLLC
Phone: 516-493-9780
Facsimile: 516-280-7376
Email: info@lifshitzlaw.com
SOURCE: Lifshitz Law Firm
View the original
press release on accesswire.com
